Literature DB >> 805794

Pituitary unresponsiveness to thyrotropin-releasing hormone in thyrotoxic patients during chronic anti-thyroid drug therapy and in rats previously treated with excess thyroid hormone.

A Harada, A Kojima, T Tsukui, T Onaya, T Yamada, K Ikejiri, Y Yukimura.   

Abstract

In an attempt to study pituitary-thyroid feedback control in thyrotoxic patients, TRH tests were performed in 10 thyrotoxic patients who were treated for varying intervals with propylthiouracil. Plasma TSH was undetectable before and after administration of 500 mug TRH in 7 patients (euthyroid or hypothyroid) after therapy for 1 to 4 months. Also, plasma TSH was undetectable before and after TRH in 3 patients who had been euthyroid for at least 6 months. To explore this abnormality, rats were made thyrotoxic by administering large doses of thyroxine or desiccated thyroid for 3 to 28 days. Discontinuation of thyroid hormone administration was followed by a significant but temporary fall of plasma thyroxine and triiodothyronine concentration below control levels. Duration of the low plasma thyroxine and triiodothyronine concentration was longer with the prolonged administration of thyroid hormone. Despite low plasma thyroxine and triiodothyronine concentrations, plasma TSH was below normal before and after administration of TRH. This unresponsiveness of the pituitary to TRH may be comparable to that found in thyrotoxic patients receiving antithyroid drugs for a certain period. Since this pituitary unresponsiveness to TRH in rats is due to a depletion of pituitary TSH content, it is suggested that depletion of pituitary TSH in thyrotoxic patients during antithyroid therapy is the cause of pituitary unresponsiveness to TRH.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 805794     DOI: 10.1210/jcem-40-6-942

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Response to TRH, serum thyroid hormone concentration, and serum markers of autoimmunity after antithyroid therapy in Graves' disease.

Authors:  B A Lamberg; A Aro; P Saarinen; T Tötterman; T Mäkinen
Journal:  J Endocrinol Invest       Date:  1978-01       Impact factor: 4.256

2.  Case reports. Graves hyperthyroidism following myxedema in a patient with recurrent carcinoma of the colon.

Authors:  G A Levine; D E Williams; J M Hershman; G N Beall
Journal:  West J Med       Date:  1978-03

3.  Value of the free triiodothyronine index in the diagnosis of hyperthyroidism.

Authors:  J D Wiener
Journal:  Eur J Nucl Med       Date:  1980-04

4.  Clinical application of a cytochemical bioassay for the determination of thyroid stimulating hormone.

Authors:  T Hashimoto; K D Döhler; D Emrich; A von zur Mühlen
Journal:  J Endocrinol Invest       Date:  1979 Oct-Dec       Impact factor: 4.256

5.  Effects of Levothyroxine Administration and Withdrawal on the Hypothalamic-Pituitary-Thyroid Axis in Euthyroid Dogs.

Authors:  V Ziglioli; D L Panciera; G C Troy; W E Monroe; K M Boes; K R Refsal
Journal:  J Vet Intern Med       Date:  2017-04-22       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.